Annual Report Focuses On The Future

BMI View: In line with the industry trend for multinational pharmaceutical companies, Boehringer Ingelheim had a difficult year in 2010. The reduction in the company's net profit in the year was substantial, but despite investor pressure the company's strategy - to focus on research and development (R&D) over profit maximisation - is in line with BMI's belief that pharmaceutical companies will ensure long-term share holder value through

To read the full article, please choose one of the following options: